EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of human cytomegalovirus cell‐free DNA in pregnant women with symptomatically infected fetuses: proof‐of‐concept study

B H W Faas iD, T Meuleman, G Astuti, A Reuss, K Stol, E A Sistermans, J Linthorst, E van Leeuwen, J Rahamat-Langendoen, F A Wilmink

Ultrasound in Obstetrics & Gynecology · 2025

DOI: 10.1002/uog.29199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ultrasound in Obstetrics & Gynecology, 2025. Verfasst von B H W Faas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud university medical center Nijmegen, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Cytomegalovirus, Cell-Free Nucleic Acids, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the presence and levels of cytomegalovirus (CMV) cell‐free DNA (cfDNA) fragments in women pregnant with a fetus with symptomatic congenital CMV (cCMV).

Methods

The study comprised nine women whose fetuses were diagnosed with cCMV between June 2019 and July 2024 at 20 + 4 to 34 + 1 weeks' gestation ( n = 8) or neonatally ( n = 1) after primary or non‐primary maternal infection. In eight women, cfDNA sequencing data from a single timepoint were analyzed, either retrospectively, on data generated from 11–13 weeks' gestation ( n = 5) or prospectively, on data generated from 20–26 weeks' gestation ( n = 3), upon the diagnosis of cCMV. In one woman (Case 6), CMV‐cfDNA analysis was performed at four timepoints: at 12 + 5 weeks (routine non‐invasive prenatal testing); 23 + 3 weeks (cCMV diagnosis); and 30 min and 12 h after termination of pregnancy (TOP) at 23 + 6 weeks.

Results

CMV‐cfDNA was detectable in all cases. Mostly low levels of CMV‐cfDNA were observed in samples obtained at 11–13 weeks' gestation and consistently high levels of CMV‐cfDNA were present in samples obtained at cCMV diagnosis. In Case 6, the level of maternal CMV‐cfDNA decreased substantially in the samples tested after TOP, compared with samples obtained before TOP.

Conclusions

Low levels of CMV‐cfDNA detected between 11 and 13 weeks may be a biomarker for severe fetal cCMV. CMV‐cfDNA analysis in the first trimester could be of added value in CMV screening, particularly for non‐primary maternal infections that cannot be identified using other methods. However, as CMV‐cfDNA is detectable in many pregnant women in the first trimester, further studies are needed to determine the predictive value of CMV‐cfDNA as a biomarker for the development of severe fetal cCMV. High levels of CMV‐cfDNA at fetal cCMV diagnosis and low levels directly after TOP suggest that the level of CMV‐cfDNA in maternal plasma may not necessarily reflect an active maternal infection, but could indicate a placental infection. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsCytomegalovirusCell-Free Nucleic AcidsPregnancy Complications, InfectiousDNA, ViralFetal DiseasesHumansFemalePregnancyAdultProof of Concept StudyRetrospective StudiesGestational AgeProspective StudiesPrenatal DiagnosisFetus

Stichwörter der Autor:innen

cell‐free DNAcytomegalovirusnon‐invasive prenatal testingscreening

Substanzen

Cell-Free Nucleic AcidsDNA, Viral

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud university medical center Nijmegen, Nijmegen, The Netherlands.
  • Department of Obstetrics and Gynecology, Radboud university medical center Nijmegen, Nijmegen, The Netherlands.
  • Department of Pediatrics, Amalia Children's Hospital, Radboud university medical center Nijmegen, Nijmegen, The Netherlands.
  • Department of Human Genetics, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Reproduction & Development research institute, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Obstetrics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: B H W Faas

Zitieren

APA

Faas, B. H. W., Meuleman, T., Astuti, G., Reuss, A., Stol, K., Sistermans, E. A., Linthorst, J., van Leeuwen, E., Rahamat-Langendoen, J., & Wilmink, F. A. (2025). Detection of human cytomegalovirus cell‐free DNA in pregnant women with symptomatically infected fetuses: proof‐of‐concept study. Ultrasound in Obstetrics & Gynecology. https://doi.org/10.1002/uog.29199

Vancouver

Faas BHW, Meuleman T, Astuti G, Reuss A, Stol K, Sistermans EA, et al. Detection of human cytomegalovirus cell‐free DNA in pregnant women with symptomatically infected fetuses: proof‐of‐concept study. Ultrasound in Obstetrics & Gynecology. 2025. doi:10.1002/uog.29199

BibTeX
@article{Faas2025,
  author = {Faas, B H W and Meuleman, T and Astuti, G and Reuss, A and Stol, K and Sistermans, E A and Linthorst, J and van Leeuwen, E and Rahamat-Langendoen, J and Wilmink, F A},
  title = {Detection of human cytomegalovirus cell‐free DNA in pregnant women with symptomatically infected fetuses: proof‐of‐concept study},
  journal = {Ultrasound in Obstetrics & Gynecology},
  year = {2025},
  doi = {10.1002/uog.29199}
}
Kostenlos starten →